Adaptive Biotechnologies (ADPT) Liabilities and Shareholders Equity (2018 - 2026)

Adaptive Biotechnologies has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $640.7 million for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 29.0% year-over-year to $640.7 million; the TTM figure through Jun 2026 stood at $2.1 billion (up 2.12% YoY), while the FY2025 annual figure was $512.7 million, down 4.94% from the prior year.
• Liabilities and Shareholders Equity came in at $640.7 million for Q2 2026 at Adaptive Biotechnologies, up from $505.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $884.2 million in Q3 2022 to a low of $490.6 million in Q3 2025.
• Average Liabilities and Shareholders Equity over 5 years is $655.6 million, with a median of $630.5 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity declined 23.5% in 2024 and gained 29.0% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $856.6 million in 2022, then decreased by 22.82% to $661.1 million in 2023, then slipped by 18.42% to $539.4 million in 2024, then retreated by 4.94% to $512.7 million in 2025, then grew by 24.95% to $640.7 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $640.7 million in Q2 2026, $505.9 million in Q1 2026, and $512.7 million in Q4 2025.